Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

The story of the pharmaceutical company Moderna almost reads like a Hollywood screenplay. In its relatively short life, it ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

Mixed options sentiment in Moderna (MRNA), with shares down $1.15 near $25.56. Options volume running well above average with 49k contracts traded ...

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand ...

Get the latest on Moderna’s Q3 earnings, analyst forecasts, COVID-19 vaccine sales impact, and what could shape MRNA’s stock ...

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...